Evaluation of alternative serum biomarkers to monitor the progression of chronic HBV and HCV infection

Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most serious health conditions affecting about 600 million people worldwide leading to a number of severe liver diseases. Due to the lack of warning signs or mild symptoms during the early stage of the infection, a...

Full description

Saved in:
Bibliographic Details
Published in:Infection, genetics and evolution genetics and evolution, 2018-03, Vol.58, p.17-22
Main Authors: Tsiomita, S., Georgopoulou, U., Doumba, P.P., Koskinas, J., Adamidis, K., Papaloukas, C., Thyphronitis, G.
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis of Variance
Biomarkers
Biomarkers - blood
Carcinoma, Hepatocellular - blood
Carcinoma, Hepatocellular - etiology
Cirrhosis
Clinical Decision-Making
Decision Support Systems, Clinical
Disease Progression
Female
HBV/HCV infection
HCC
Hepacivirus
Hepatitis B virus
Hepatitis B, Chronic - blood
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - virology
Hepatitis C, Chronic - blood
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - virology
Humans
Liver Cirrhosis - blood
Liver Cirrhosis - etiology
Liver Neoplasms - blood
Liver Neoplasms - etiology
Male
Middle Aged
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most serious health conditions affecting about 600 million people worldwide leading to a number of severe liver diseases. Due to the lack of warning signs or mild symptoms during the early stage of the infection, a molecular signature associated with disease progression would be useful. Based on our recent paper where candidate biomarkers were determined through topological and modularity analysis of protein interaction networks (PINs), this study was focused on the evaluation of MIF, TNFRSF1A, FAS and TMSB4X as diagnostic biomarkers in chronic HBV and HCV infections. The aim was to establish a molecular profile, by combining those markers, that would discriminate the different stages during the progression of chronic hepatitis. One hundred and fifteen patients infected with HBV or HCV categorized into three groups: non-cirrhotic, cirrhotic and with HCC, and 20 healthy subjects were enrolled in this study. Serum levels of the aforementioned factors were measured by ELISA. TNFRSF1A serum levels appeared statistically significantly increased in all patient groups compared to control group with a p-value of
ISSN:1567-1348
1567-7257
DOI:10.1016/j.meegid.2017.12.002